Actinium Pharmaceuticals, Inc. — Director's Dealing 2021

Sep 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Actinium Pharmaceuticals, Inc. (ATNM)
CIK: 0001388320
Period of Report: 2021-09-01

Reporting Person: Berger Mark Stanley (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-01	Stock Option (Right to Buy)	$6.07	A	67164	Acquired	2031-09-01	Common Stock (67164)	Direct

Footnotes

F1: This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant.

F2: Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested.